Amsterdam, February 10, 2026

Full year and Q4 highlights

   -- Comparable order intake growth 6% in 2025; up 7% in Q4 
 
   -- Group sales of EUR 17.8 billion in 2025, EUR 5.1 billion in Q4; 
      comparable sales growth 2% in 2025, 7% in Q4 
 
   -- Income from operations was EUR 1,424 million in 2025; EUR 540 million in 
      Q4 
 
   -- Adjusted EBITA margin increased 80 basis points to 12.3% of sales in 
      2025; up 160 basis points to 15.1% in Q4 
 
   -- Operating cash flow of EUR 1,172 million in 2025; EUR 1,391 million in Q4 
 
   -- Free cash flow of EUR 512 million in 2025; EUR 1,200 million in Q4 
 
   -- Productivity savings of EUR 0.8 billion in 2025; delivered 2023-2025 
      target of EUR 2.5 billion 
 
   -- Proposed 2025 dividend of EUR 0.85 per share, in shares or cash at the 
      option of the shareholder 
 
   -- Outlook for 2026 published 

Capital Markets Day

   -- Philips sets out plan to drive profitable growth to deliver sustainable 
      value, including new, integrated 2030 Impact Ambitions. Plan comprises 
      three pillars: segment-specific growth strategies, innovation as a key 
      growth driver and continued disciplined execution 
 
   -- Philips publishes 2026-2028 financial targets, including mid-single-digit 
      comparable sales growth CAGR over the period and mid-teens Adjusted EBITA 
      margin in 2028 

Roy Jakobs, CEO of Royal Philips:

"In 2025, we delivered on our commitments as we scaled better care for more people. We strengthened our company while navigating a dynamic macro-environment. We ended the year with strong order growth and sales, robust margin expansion despite tariffs, solid cash generation, and we exit the year with a robust balance sheet.

Over the past three years, we have strengthened Philips at its core. Our employees live our culture of impact with care, guided by an expert leadership team. We prioritized quality, built supply chain resilience, and simplified how we operate. This focus delivered customer-driven innovation. We launched the new Azurion neuro biplane platform to advance minimally invasive diagnosis and treatment for neurovascular patients. We presented our latest innovations in 3.0T helium-free MR. We introduced centralized patient monitoring designed for enterprise-scale care. We expanded our OneBlade platform into an all-body solution. We remained true to our purpose, and delivered on our promise to create value with sustainable impact.

Today we enter our next phase of driving profitable growth. Our unique platform-based innovations in healthcare and self-care, combined with our strong execution capability and fully integrated impact ambitions, provide Philips with a strong growth foundation in a world where data and AI are rapidly transforming care. These structural advantages enable us to move forward with confidence.

Our talented, passionate team is energized and executing with purpose and discipline as we drive meaningful impact for patients, consumers and health systems."

Group and segment performance

For the quarter, comparable order intake increased 7%, supported by growth in both Diagnosis & Treatment and Connected Care and continued strong performance in North America. Group comparable sales increased 7%, with growth in all segments.

Adjusted EBITA margin increased strongly by 160 basis points to 15.1% in the quarter, driven by higher sales, gross margin from recently launched innovations, and productivity, more than offsetting the impact from incremental tariffs. Free cash flow was EUR 1,200 million.

For the full year, comparable order intake increased 6% and comparable sales growth was 2%. Adjusted EBITA increased 80 basis points to 12.3%, driven by underlying gross margin and strong productivity, which more than offset the impact from increased tariffs after substantial mitigations. Free cash flow was EUR 512 million. Free cash flow included a EUR 1,025 million payment for Respironics recall-related medical monitoring and personal injury settlements in the US.

Diagnosis & Treatment comparable sales increased 4% in Q4. Adjusted EBITA margin was 11.8% in Q4, down 30 basis points, mainly due to tariffs and partly offset by higher gross margin from innovation and productivity. For the full year, the Diagnosis & Treatment Businesses recorded 0% comparable sales growth and an Adjusted EBITA margin of 11.7%.

Connected Care comparable sales increased 7% in Q4. Adjusted EBITA margin improved 150 basis points to 16.5% in Q4, driven by operating leverage, improved gross margin and productivity, and partly offset by tariffs. For the full year, the Connected Care Businesses recorded a 3% comparable sales increase, and Adjusted EBITA margin increased to 10.7%.

Personal Health comparable sales increased 14% in Q4. Adjusted EBITA margin increased 500 basis points to 23.0% in Q4, driven by higher sales and productivity, and partly offset by tariffs. For the full year, Personal Health comparable sales were 8%, and Adjusted EBITA margin increased to 18.0%.

Innovation highlights

   -- At RSNA, Philips presented three world-first innovations, including the 
      world's first BlueSeal helium-free 3.0T MR magnet [1]; Philips Verida, 
      the world's first detector-based Spectral CT fully powered by AI, and the 
      next generation of Philips Vue PACS with a zero-footprint, web-based 
      diagnostic viewer. 
 
   -- Philips signed in December 2025 and completed in January 2026 the 
      acquisition of SpectraWAVE, delivering the most advanced and complete 
      portfolio for coronary interventional procedures in the industry. 
 
   -- Philips signed a five-year strategic partnership with AdventHealth, a 
      large not-for-profit healthcare system in the US with more than 50 
      hospital campuses across nine states. The collaboration will replace and 
      upgrade patient monitors across the network, coupled with Philips' 
      Software Evolution Service program, supporting standardized workflows, 
      improved patient safety, and a future-ready monitoring infrastructure 
      across care settings. 
 
   -- Philips secured a landmark competitive radiology IT partnership with one 
      of the largest private healthcare providers in the US. The collaboration 
      will standardize Philips' cloud-based HealthSuite Imaging PACS, hosted on 
      Amazon Web Services, across almost 30 hospitals, replacing competitive 
      systems and supporting millions of imaging studies annually with scalable, 
      efficient diagnostic workflows. 
 
   -- At the China International Import Expo, Philips revealed new oral care, 
      grooming, and haircare innovations, including Sonicare Prestige 9900 and 
      Norelco i9000 Prestige, reinforcing our commitment to meaningful, locally 
      relevant innovation in China. 
 
   -- The RADIQAL clinical trial has enrolled almost half of the targeted 
      patients, testing the effectiveness of Philips' new ultra-low-dose 
      technology, SmartIQ, in reducing radiation without impacting procedure 
      performance. 
 
   -- Philips was named a Clarivate Top 100 Global Innovator for 2026 for the 
      13th consecutive year, ranking as the highest medical technology company, 
      with industry-leading R&D investment and a strong innovation pipeline. 

[1] 3.0T Helium-free MR is Work in Progress and not available in any jurisdiction. Its future availability cannot be guaranteed.

Productivity

Philips has successfully delivered its three-year, EUR 2.5 billion productivity program, including EUR 0.8 billion of productivity savings in 2025.

Outlook

For 2026, Philips expects:

   -- Comparable sales growth: 3%-4.5% 
 
   -- Adjusted EBITA margin: 12.5%-13.0% 
 
   -- Free cash flow: EUR 1.3-1.5 billion 

Within the context of an uncertain macro-environment, Philips' 2026 outlook includes currently known tariffs. It excludes ongoing Philips Respironics-related proceedings, including the investigation by the US Department of Justice.

Capital allocation

Philips intends to submit to the 2026 Annual General Meeting of Shareholders a proposal to declare a dividend of EUR 0.85 per common share, in shares or cash at the option of the shareholder.

Capital Markets Day

Driving profitable growth to deliver sustainable value

Later today, Philips will present its plan to drive profitable growth to deliver sustainable value. The company enters this next phase of its strategy having strengthened its core fundamentals, team and culture, resilience and execution agility. Building on this foundation, Philips is leveraging its scalable platform-based innovation advantage, supported by a large global customer base and a trusted brand across healthcare and self-care. There are three pillars to this plan:

Creating value through segment-specific strategies that reflect the distinct needs of different customers, markets and technologies. By making deliberate choices on where to compete, how to win, and how to allocate capital, the company maximizes the potential of each segment while delivering consistent value across its portfolio.

Innovation as a key growth driver with platform-based solutions as our unique differentiator. Customer- and consumer-centric innovation and platform-based solutions integrate hardware, software, data, and AI. This will enable Philips to address clinical, operational and everyday health challenges, enabling better outcomes, improved experiences, and sustainable profitable growth.

Disciplined execution underpins this approach. Quality and compliance remain Philips' number one priority. Resilient operations will ensure Philips can continue to act with agility in an uncertain macro-environment. Simplification and AI will drive enhanced productivity and speed. The company will step-up commercial and service excellence. Philips will translate innovation into impact, scale solutions effectively, and deliver reliably on its commitments.

(MORE TO FOLLOW) Dow Jones Newswires

February 10, 2026 01:00 ET (06:00 GMT)